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Endothelin (ET) , which mediates vasoconstrictor and vaso-
dilator activities via multiple receptor subtypes, has been im-
plicated in the control of blood flow and vascular tone in 
human skin, and possibly in the abnormal vasoconstrictor 
response in primary Raynaud's phenomenon and systemic 
sclerosis. Using in vitro autoradiography we have examined 
the endothelin-binding characteristics and receptor subtypes 
of human skin, and sought to provide evidence for endothe-
lin receptor regulation in skin from patients with primary or 
secondary Raynaud's phenomenon. Specific 1251-ET_l and 
1251 - ET -3 binding sites were localized to microvessels of the 
sub-epidermal plexus and dermal papillae, larger blood ves-
sels, sweat glands, epidermis, and hair follicles. Both ETA and 
T he potent vasoconstrictor peptide endothelin-1 (ET-1), first isolated from vascular endothelial cells [1], and the related isoforms ET -2 and ET -3 are synthe-sized by the vascular endothelium of many tissues in-cluding human skin [2]. As well as vasoconstriction, 
endothelins mediate endothelium-dependent vasodilation via the 
release of J;?rostaglandins and endothelium-derived relaxing factor 
(EDRF) [3J, and are potent mitogens of many cell types, including 
rat vascular smooth muscle [4], rat brain endothelial cells [5] , glo-
merular mesangial cells [6] , and human dermal fibroblasts [7] . 
At least two ET-receptor subtypes have been identified, and are 
characterized by their differing affinities for ET -isopeptides [8 ,9]. 
The ET-1/ET-2 selective subtype (ETA) is present in vascular 
smooth muscle, and mediates vasoconstriction via phospholipase C 
and intracellular calcium ion mobilization [10,11]. An ETA-like 
subtype is also found in vascular endothelium and may attenuate the 
vasodilatory activity of other peptides [12]. The non-selective sub-
type (ET B) is localized to vascular endothelium, mediating vasodila-
tion [13,14], via EDRF release, and has recently been demonstrated 
in vascular smooth muscle cells, linkcd to vasoconstriction [15,16]. 
ET has a direct vasoconstrictor effect on human skin microvascu-
lature [17,18], and regulates the release of prostaglandin E2 and 
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ET B receptors were demonstrated in microvessels and other 
structures. ET receptor heterogeneity in skin vasculature 
suggests a role for ET as an autocrine/paracrine regulator of 
vasoconstrictor and vasodilator pathways in human skin. The 
presence of binding sites in epidermis and hair follicles sug-
gests a possible mitogenic function for endothelin in human 
skin. Endothelin-binding density was significantly higher 
(p < 0.05) in microvessels of skin from patients with sys-
temic sclerosis but not significantly different in Raynaud's 
phenomenon patients, compared to controls. Lack of down 
regulation of ET receptors in Raynaud's phenomenon and 
systemic sclerosis may contribute to the pathogenesis of va-
sospasm in these diseases.] Invest Dermatoll 01:73 - 78, 1993 
intracellular cAMP levels in cultured skin microvascular endothe-
lium, suggesting an aucocrinc/paracrine mode of vascular tone regu-
lation by locally produced ET in human skin [2]. 
Increased plasma levels of ET -1 have been associated with a num-
ber of circulatory disorders, including cerebral vasospasm [19] , 
essential hypertension [20], and Raynaud's I?henomenoll [21,22]. 
Similar findings have been observed in patients with Raynaud's 
phenomenon associated with systemic sclerosis [7,23,24]. Elevated 
ET in plasma along with reduced calcitonin gene-related peptide-
immunoreactivity in digital skin may playa role in the digital vaso-
spasm of Raynaud's phcnomenon [25,26]. 
We hypothesize that ET isopeptides may mediate their vascular 
activities via multiple receptor subtypes in human skin, and that 
regulation ofET-receptors in primary Raynaud's phenomenon and 
systemic sclerosis may contribute towards digital vasospasm in these 
diseases. In these studies, therefore, we have examined the endothe-
lin receptor- binding characteristics of human skin, and have deter-
mined the relative ET-binding site densities in skin frOm patients 
with primary Raynaud's phenomenon and Raynaud's phenomenon 
in association with systemic sclerosis, and compared these to find-
ings in normal skin. 
MATERIALS AND METHODS 
Tissue Preparation Skin biopsies were taken from the dorsum of 
a proximal phalanx o~ seven normal women (mean age 26 ycars, 
range 24-32 years), SIX women and one man with primary Ray-
naud's phenomenon (mean age 41.57 years, range 19 - 73 years), 
and three women and two men with Raynaud's phenomenon in 
association with late-stage systcmic sclcrosis (mean age 46 ycars, 
range 21-80 years). Primary Raynaud's phenomcnon was diag-
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nosed using the criteria of Allen and Brown (1932) [27] and sys-
temic sclerosis was diagnosed according to the criteria of the Ameri-
can Rheumatism Association (1980). The tissues from the three 
groups of patients were used only for the comparison of endothelin 
receptor - binding density. Because of the limitin g size of skin biop-
sies, binding characterization was carried out on a separate group of 
biopsies from six normal men (mean age 42.5 years, range 23 - 58 
years) . The data obtained from these tissues were not included in the 
three-way comparison. The small size of the biopsies unfortunately 
meant that full characterization of ET -binding sites in Raynaud's 
phenomenon and systemic sclerosis could not be performed in this 
study. Biopsies were immediately embedded in mounting medium 
(Tissue T ek, Miles Inc., USA), frozen in melting dichlorodifluoro-
methane (Arcton-12, ICI, Runcorn, UK), and stored at -40°e. 
Human dermal microvascular endothelial cells (HDMEC) were 
isolated from neonatal foreskin and cultured as previously described 
[28J, plated onto microscope slides, and stored unfixed at -40°C. 
Ligand-Binding Studies Ten-micrometer sections of human 
skin cut perpendicular to the skin surface were thaw-mounted onto 
Vectabond-treated microscope slides (Vector Laboratories, Peter-
borough, UK), and stored at 4°C for up to 2 h, prior to use. Tissue 
sections and plated HDMEC cultures were pte-illcubated in 50 mM 
Tris-HCI buffer (pH 7.4), containing 5 rnM MgC12, 100 mM 
NaCI, and 40 mg/J bacitracin for 15 min at 20°C, followed by 
incubation in the same buffer containing 200 pM (3-(1 25IJiodotyro-
syl) endothelin-l or (3_(!25I]iodotyrosyI6) ET -3 (1251 - ET -1, 1251_ 
ET-3, 74 TBq/mmol, Amersham International, UK), 10 gil bo-
vine serum albumen (Sigma Chemical Company, Poole, UK), and 
10-6 M phosphoramidon for 120 min at 20°e. Non-specific bind-
ing was determined by incubating adjacent sections in the presence 
of 10- 6 M unlabeled porcine ET-l or ET-3, respectively. 
The time course of association of 200 pM 1251 - ET -1 to human 
skin sections was determined by incubating serial sections for in-
creasing lengths of time (5-180 min) at 20 °C. Dissociation was 
investigated by the addition of 10- 6 M unlabeled ET -1 for increas-
ing time periods, following 120-min incubation, at 20 C e. 
Competitiv~ inhibition of 1251 -ET -1 binding was investigated by 
incubating sections with 200 pM 125I-ET-1 for 120 min in the 
presence of increasing concentrations of unlabeled ET -1 or ET-3 
(10- 12 -10-6 M). The effect of the specific ETa receptor agonists 
[Ala3,11 ,18 Nle?] ET-l [29J and sarafotoxin S6c [30J, on 1251_ET_l 
binding to human skin and to HDMEC cultures was examined by 
pre-incubating sections for 30 min with each inhibitor (10-7 M) 
prior to incubation as normal. Specificity of 1251 - ET -1 binding was 
examined in the presence of an excess (10- 6 M) of the unrelated 
peptides CGRP, vasoactive intestinal peptide, angiotensin II, and 
atrial natriuretic peptide. FoJlowing incubation, sections were 
rinsed in ice-cold pre-incubation buffer (2 X 5 min), quickly 
washed in ice-cold distilled water, and dried under a cold stream 
of air. 
Autoradiography and Image Analysis Labeled sections were 
apposed to Hyperfilm-3H (Amersham, UK), alongside radioactive 
polymer standard sections (American Radiolabelled Chemicals Inc., 
St. Louis, USA), for 1 - 2 d at 4 ° C. Autoradiograms were developed 
in Kodak D-19 developer for 5 min at 20 o e, and quantified by 
computer-assisted microdensitometry, using a Kontron !BAS 20 
image-analysis system (Kontron Elektronik Ltd., Watford, UK). 
Optical densities obtained from the autoradiographical images were 
converted to binding densities in amols per mm2 (amol mm-2) using 
a logarithmic calibration curve generated from the radio labeled 
standards. Estimations of specific 1251 -ET -1 binding were deter-
mined as the difference between measurements for sections incu-
bated with or without excess unlabeled peptide (non-specific and 
total binding, respectively). 
Greater anatomical resolution for localization of 1251 -ET -1 bind-
ing sites at the cellular level was achieved by microautoradiography. 
Following exposure to film, sections were fixed by immersion in 
Bouin's fixative for 1 h, followed by washes in phosphate-buffered 
saline (PBS, 0.01 M). After rinsing in distilled water and drying, 
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Figure 1. Representative dark field autoradiographic images ofconsecutiv~ 
human control skin sections showing total (A) and non-specific (B) 1251, 
ET-l binding, and total (C) and non-specific (D) 1251_ ET_3 binding it( 
dermal capillaries (de), sweat glands (g), epidermis (e), and hair follicle (h). 
Bar, 1.0 mID. 
sections were dipped in K5 liquid emulsion (HEord Ltd., Cheshire, 
UK) at 43 ° C, dried, and stored for exposure at 4 0 C for 7 - 8 d, 
Dipped slides were then developed in Kodak D-19 developer fo~ 
3 min, washed, stained with haematoxilyn and eosin, dried, and 
mounted under synthetic medium (Pertex, Cell path pic., Hemel 
Hemstead, UK). 
Calculations and Statistical Analysis Analysis of association, 
dissociation, and competitive inhibition data was performed b· 
non-linear regression using GraphP AD INPLOT version 3.11 
(GraphPAD software, San Diego, CA). Data from competitive inhi, 
bition of 12sJ_ET_l binding by unlabeled porcine ET-l and ET-3 
was fitted to a one- or two-site competition curve to provide esti, 
mates of the concentration of unlabeled peptide required to produc~ 
50% maximum inhibition (ICso), the maximum binding capacit}' 
(Bm ... ), and a Hill coefficient (nH), for each skin structure. Fitting ot 
data to a two-site competition curve assumes that the competing 
ligand is binding with differing affinities to two sub-populations ot 
receptors [31] . Following curve fitting, an f-test (by INPLOT 4, 
GraphPAD software) was used to determine whether inhibition 
data was fitted better to a one-site or to a two-site competition curve. 
Hill coefficients were used to give an indication of the slope of a 
curve, wherein a slope of 1.0 represents inhibition by a non-subtype 
specific ligand [31J. The Bm .. for 125I-ET-l binding was calculated 
from competitive inhibition by unl abeled ET-1 as Bm.x': Bo X 
IC5o /[L], where Bo represents specific binding, and [L] is the ligand 
concentration [32] . 
Analysis of variance (ANOVA, by GraphPAD InStat version 
1.14) was used for comparisons of IC5o , Em ... and nH values be, 
tween skin structures, and for comparing the effects of [Ala3•11.1, 
Nle?] ET -1, and sarafotoxill S6c pretreatment on ET -1 - binding 
density between structures. ET-l- binding densities in normal skiJi 
were compared with skin from Raynaud's phenomenon and sys, 
temic sclerosis patients by AN OVA and by two-tailed t test, takin& 
differences with p values less than 0.05 as significant. Results wer~ 
also tested for normality using the Shapiro-Wilk W test. All data a:r 
expressed as the mean ± standard error (SEM). Measurements ot 
receptor density for this comparison were carried out in the sub-epj, 
dermal plexus and sweat glands where previous studies have showJ\ 
the changes in neuronal peptides to be mainly concentrated [26]. 
RESULTS 
Bindiug Site Localization Specific 12sI _ET_ l and 12 5I _ET_3 
binding sites were localized by macroautoradiography to tissue sec, 
tions of all subjects studied (Fig 1). Microautoradiography of dippe~ 1 
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Figure 2. Light microscopy of microautoradiographs demonstrating total 
125I_ET_1 binding to capillary loops of dermal papillae and sub-epidermal 
plexus in skin from (A) normal and (B) systemic sclerosis patients . Specific 
binding to epidermis is not clear because silver grains over this structure are 
on a different focusing plane. Bar, 100/1m. 
slide preparations demonstrated specific binding over capillaries of 
the sub-epidermal plexus; capillary loops of the dermal papillae (Fig 
2A); and capillary plexuses of sweat glands, hair follicl es, and se-
baceous glands. All capillary plexuses possessed binding sites for 
1251_ET_1 and 1251_ET_3 , 1251_ET_1 binding densities beingappar-
ently higher than those for 1251 -ET -3. Smooth muscle of arterioles 
in the deep dermis possessed a high density of 1251_ET_1 binding 
sites, whereas variable levels were seen over venules of the dennis. 
Arrector pili smooth muscle possessed low levels of specific 1251_ 
ET -1 binding. Arterioles and venules of the deep dermis showed no 
specific 1251_ET_3 binding. A high density of specific 1251_ET_l 
binding and a much lower density of specific 1251_ET_3 binding 
was observed over the basal cell layer of the epidermis and the broad 
external root sheath of hair follicles, continuous with the basal cell 
layer. No specific 1251_ET_l or 1251_ET_3 binding was evident in 
epithelial layers of sweat glands. 
Non-specific 1251_ET -1 binding was low in all vascular structures 
« 5%), and in the stratified epidermal layers, sweat glands, and hair 
follicles (10- 20%). Non-specific 1251 -ET -3 binding was high in all 
skin structures, being 30 - 40% of total in subepidermal plexus and 
sweat glands and 70 - 80% of total in epidermis and hair follicle . 
Specific 1251_ET_l and 1251_ET_3 binding sites were also local-
ized to cultured HDMEC. Binding densities for both ligands in 
these cells were much lower than those seen in skin sections . There 
was also a high proportion of non-specific 1251 - ET -1 and 1251 - ET-
3 binding to these preparations, 30% and 60% of total, respectively. 
HDMEC also possessed approximately equal proportions of specific 
1251_ET_l and 1251_ET_3 binding. 
Characterization of ET Binding Sites Binding of 2001M 
1251_ ET_1 to the sub-epidermal plexus of human skin reache an 
apparent equilibrium after 120 min incubation, and was found to be 
only partially displaceable after 2 - 4 h following addition of 10-6 M 
unlabeled ET-1 to sections at equilibrium (Fig 3). The association 
rate with other skin structures was similar, but the percentage of 
displaceable binding after 4 h dissociation was significantly lower 
(p = 0.Q15). 
1251_ET_1 binding to all four skin structures was completely in-
hibited by co-incubation with unlabeled ET- 1 or ET -3 (Fig 4). Data 
from inhibition by ET -1 was best fitted to a one-site competition 
curve for each skin structure and provided significantly different 
inhibitor potencies (IC50) and binding capacities (Bm ",,) between 
structures (Table I) . Hill coefficients for these curves were all close 
to -1.0, with no significant differences between them (p > 0.8 by 
ANOV A), suggesting that unlabeled ET -1 binds with equal affinity 
to the total population of 1251_ET_l binding sites. 
Data from inhibition by unlabeled ET -3 was found to fit signifi-
cantly better to a two-site competition curve in all four skin struc-
tures (p < 0.05), following an f test statistical comparison of the 
two-curve fitting methods (Fig 4). This suggests the presence of 
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Figure 3. Time course of associa tion~) and dissociation (D) of 12sl_ET_1 
binding to sub-epidermal plexus of normal human skin. Each poillt repre-
sents the mean and SEM of measurements in sections from six people, 
expressed as a percentage of maximum specific binding (4 h). Dissociation 
initiated after 2 h incubation by the addition of 10- 6 M unlabeled ET-1. 
two populations of ET receptors, one with high affinity for ET-3 
(low IC50 value) and one with low affinity for ET-3 (high IC50 
value), corresponding to ET D and ET 1\ receptors, respectively. Sig-
nificant differences in IC50 values for both populations of binding 
sites (Table I) and their relative proportion (Fig 5) were seen be-
tween skin structures. 
Binding of 1251_ET_l to sites in sub-epidermal plexus, sweat 
glands, and epidermis was inhibited by pre-incubating sections w ith 
[Ala3.11.18 Nle7] ET-1 and sarafotoxin S6c (10- 7 M) , before incubat-
ing with 200 pM 1251 - ET -1 as normal. The magnitude of this 
inhibition varied significantly between structures for both inhibi-
tors (p < 0.0001, Fig 6). 1251_ET_l binding to HDMECs was com-
pletely abolished by pre-incubation with [Ala3.11 .18 Nle7] ET-l at 
the same concentration, w hereas pre-incubation with sarafotoxin 
S6c reduced binding by 80%. 1251_ET_l binding was unaffected by 
the inclusion of 10- 6 M CGRP, angiotensin-II, atrial natriuretic 
peptide, or vasoactive intestinal peptide in the incubation buffer 
(data not shown). 
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Figure 4. Competitive inhibition of specific 1251 - ET -1 binding to sub-epi-
dermal plexus of normal human skin, in the presence of increasing concen-
trations of unlabeled ET -1 ~, one-site model) and ET -3 (0, two-site 
model). Each poillt represents the mean and SEM of samples from six people, 
expressed as a percentage of maximum specific binding. 
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Table I. Competitive Inhibition of 125I_ET_1 Binding in Human SkinQ 
ET-l as Competitor (One-Site Model) ET -3 as Competitor (Two-Site Model) 
Structure ICsob Bmu b -nH ICsob (Site A) ICsob (Site B) 
SEP (n = 6) 0.20 ± 0.04 61.1 ± 10.4 1.08 ± 0.15 104.6 ± 47.3 0.04 ± 0.02 
SWG (n=4) 0.36 ± 0.06' 148.8 ± 36.8' 1.09 ± 0.18' 118.6±47.1 0.80 ± 0.46 
EPD (11 = 6) 0.38 ± 0.06 149.0 ± 22.4 1.16 ± 0.01 78.3 ± 31.0 0.18 ± 0.15 
HRF (n = 5) 0.99 ± 0.03J 496.0 ± 161.9J 1.31 ± 0.40J 1222 ± 425.0 1.17 ± 0.93 
• Mean IC50 (11M). B_ (amol mm- 2). and Hill coefficient (-nH) values with SEM from sub-epidermal plexus (SEP). sweat glands (SWG). epidermis (EPD). and hair follicl e 
(HRF). Sites A and B represent ETA and ET D receptors. respectively . 
• Significant differences between the four structures (p < 0.05 by ANOVA). n = number of samples used. except' n = 3. J n = 4. 
Binding Densities in Raynaud's phenomenon and Systemic 
Sclerosis In skin from patients with primary Raynaud 's phenome-
non and systemic sclerosis. specific 1251-ET-l binding sites were 
localized to the sub-epidermal capillary plexus. dermal papillae, 
capillary plexuses of all skin structures and to other vascular tissue, 
as we ll as epidermis and hair follicles. The relative densities between 
structures were similar to those seen in normal skin. 
Significant differences in 1251 - ET -1 binding densities for capil-
laries of sub-epidermal plexus were found between skin samples 
from control, primary Raynaud's phenomenon, and systemic sclero-
sis patients (p = 0.012, by ANOVA). Similar differences between 
groups were also seen for sweat glands (p = 0.030, by ANOVA). 
Individual t tests revealed that binding densities in sub-epidermal 
plexus of systemic sclerosis patients were significantly higher than 
in control or Raynaud's phenomenon patients (p < 0.05), but were 
not significantly different between control and Raynaud's phenome-
non samples (Figs 2B and 7). Marginally significant differences in 
the mean age of the three groups of patients were observed. The 
mean age of the control group was slightly lower than the mean 
ages of the Raynaud's phenomenon group (p = 0.041) and the sys-
temic sclerosis group (p = 0.046). Non-specific 125I_ET_l binding 
was not significantly different between skin from control, Ray-
naud's phenomenon. and systemic sclerosis patients. 
DISCUSSION 
W e have demonstrated that microvessels. sweat glands, epidermis, 
and hair fo ll icles of human skin possess specific 125I_ET_l and 
125I_ET_3 binding sites. Binding inhibition with ET isoforms, pre-
incubation with specific ET-receptor agonists. and lack of inhibi-
* 
HRF 
Figure 5. Relative proportion ofET A and ET D receptor subtypes in sub-epi-
dermal plexus (SEP). epidermis (EPD), sweat glands (SWG). and hair folli-
cle (HRF) of normal human skin. Data from non-linear regress ion analysis 
of competition inhibition by unlabeled ET -3 giving proportion of ETA and 
ET 0 receptors expressed as a percentage of maximum specific 125) -ET-l 
binding. Data expressed as mean and SEM. for six different samples. ' Signifi-
cantly higher proportion of ETA in HRF compared to SEP (p = 0.0041) and 
EPD (p = 0.016). No significant differences were apparent between SEP. 
EPD. and SWG. 
tion by unrelated peptides provide further evidence that these bind-
ing sites correspond to functional receptors. 
We have identified, using binding-inhibition studies, two sub-
classes of ET receptor in sub-epidermal plexus of human skin. One 
of these was inhibited with high potency by both ET-1 and ET-3 
(non-isopeptide selective) and probably corresponds to the ET B re-
ceptor [9] . The other was inhibited with high potency by ET-1 but 
with low potency by ET-3 (ET-1 selective), corresponding to the 
ET A receptor [8] . This heterogeneity was further illustrated by the 
incomplete inhibition of1 25J - ET -1 binding by [Ala3•11 •18 N le7] ET-
1 and sarafotoxin S6c and the lower 1251 - ET -3 binding density 
compared to 125I_ET_1 in these vessels. Due to the close association 
of pericytes with the endothelium of these micro vessels, we have 
been unable to determine the exact distribution of ET -receptor sub-
types between the two cell layers. As a consequence of this, the 
1251 - ET -1 and 1251 - ET -3 binding observed in tissue sections may 
be localized to endothelium and/or pericytes. 
Binding studies with cultured HDMEC demonstrate complete 
inhibition of 125I_ET_l binding by [Ala3•11 •18 Nle7] ET-l and ap-
proximately equal density of 125I_ET_1 and 125J_ET_3 binding, 
indicative of non-selective ET -binding sites (presumably ET B)' but 
not the ETA subtype. However, changes in receptor expression in 
these cells may have occurred during the culturing process, possibly 
resulting in ETA receptor down-regulation. Furthermore, ET -re-
ceptor heterogeneity in both endothelium and pericytes of cutane-
ous vessels remains a possibility, because both ETA and ET B subtypes 
have been demonstrated in endothelium [12,14] and in smooth 
muscle cells [15,16]. 
ET receptors linked to vasoconstrictor pathways have been dem-
onstrated on bovine retinal capillary pericytes [33], and human der-
mal pericytes contain a smooth muscle contractile element [34]. 
ET -binding sites on pericytes of human skin microvasculature may 
therefore corroborate the role of ET as a vasoconstrictor in the 
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Figure 6. Specific 125I_ET_l binding remaining in human skin compart-
ments (see Fig 5 for abbreviations) after pre-incubation with 10-7 M 
[Ala,·Il·Is Nle7] ET-l and sarafotoxin S6, for 30 min, prior to incubation. 
Binding significantly reduced in SEP. EPD, and SWG (*p < 0.05). 
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Figure 7. Relative specific 1251_ ET -1 binding densities in sub-epidermal 
plexus (SEP) and sweat glands (SWG) of skin from normal (n = 7), systemic 
sclerosis (n = 5), and primary Raynaud's phenomenon (n = 7) patients. 
Data expressed as the mean with SEM, and are the mean of repeated deter-
minations and repeated measurement of each determination. Significant 
differences in density seen between control and systemic sclerosis (Op < 
0.05). 
capillary plexus of human skin [17,18J. Taken together with 
previous studies, our results confirm the importance of ET as a 
regulator of blood flow in the superficial as well as deep dermis of 
human skin, acting through both vasoconstrictor and vasodilator 
pathways. 
ET stimulates the growth of many cell types [6,35J and acts in 
synergy with other peptides such as epidermal growth factor [36J. 
The apparent mediation of cellular growth by ET, specifically via 
ETA rece.£tors in smooth muscle cells [37J and rat cerebra l endothe-
lial cells l5J, suggests that ET may be involved in capillary growth in 
skin development and healing. Furthermore, the high density of 
ETA receptors in hair follicles, epidermis, and sweat glands suggests 
that ET may act as a mitogen in these structures. The significance of 
a high proportion of the ET B subtype in epidermis, however, is not 
known. 
In this study, we have demonstrated significantly higher 1251_ 
ET -1 binding densities in microvessels of the sub-epidermal plexus 
and dermal papillae in skin from patients with systemic sclerosis, but 
not patients with Raynaud's phenomenon, compared to controls. It 
is unlikely that age differences between groups of patients have 
contributed to these changes, because both disease groups were of 
higher mean age than controls, but only the systemic sclerosis group 
demonstrated higher 1251 -ET- l binding density. Increased binding 
density in systemic sclerosis may be associated with a high density of 
binding sites on proliferating pericytes and fibroblasts, involved 
with vascular thickening and perivascu lar fibrosis [7,38,39J. If this 
contributes to digital vasospasm then a similar increase should also 
be apparent in primary Raynaud's phenomenon. However, no 
changes of binding densities in primary Raynaud's phenomenon 
occurred, as may have been expected in response to increased plasma 
ET levels [21,22,40J . 
Reduced production of vasodilatory substances such as histamine, 
prostaglandin E2 and prostaglandin 12 have been suggested to occur 
in Raynaud's phenomenon [41 J, and reduced levels of endogenous 
CGRP and CGRP-immunoreactive nerves have been demonstrated 
in Raynaud's phenomenon and systemic sclerosis skin [25,26J . We 
suggest that increased or unchanged ET receptor number and/or 
affi nity on skin microvessels in Raynaud's phenomenon and sys-
temic sclerosis, together with elevated plasma ET and a reduced 
vasodilatory capacity, may result in unbalanced microvessel tonal 
control, favoring vasoconstriction [21,42J. 
In conclusion, our results demonstrate the existence of mu ltiple 
ET-receptor subtypes in microvessels and other structures of human 
skin. Multiple receptor subtypes on pericytes and endothelium of 
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dermal microvessels may be responsible for the vasoconstrictor and 
vasodilator actions of ET in human skin. In primary Raynaud 's 
phenomenon and systemic sclerosis, alterations in ET -receptor 
characteristics may contribute to the pathogenesis of these condi-
tions. Therefore, control of vascular tone and blood flow in normal 
and diseased skin involves a complex interaction between ET iso-
peptides, ET -receptor subtypes, and their alternative vasoconstric-
tor and vasodilator pathways. 
We lVould like to tiJallk Dr. David Waishforva/llable advice ill the preparatioll of the 
lIIall IIscript. 
Grallts alldfillallcial sllpport were provided by the Colt Foulldatioll, The BUPA 
Medical FOlllldatio ll, alld The Freclllasoll 's Gralld Charity. 
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ANNOUNCEMENT 
Letters of nomination are being accepted for recipients of the Dermatology Foundation's two 
distinguished awards. 
Clark W _ Finnerud Award: Established in 1971 in honor of Dr. Finnerud and awarded each 
year to all individual who has devoted extraordinary time and talent as a part-time teacher and 
clinician. 
Practitioner of the Year Award: Established in 1976 and awarded each year to an individual 
for exemplary service as a practitioner of dermatology. 
Letters of nomination should include background information on the nominee which would 
qualify him or her for the award. A curriculum vitae is also requested. Submit all nominations 
and supporting letters by June IS, 1993 to the FinnerudjPractitioner Award, Dermatology 
Foundation, 1560 Sherman Avenue, Ste. 302, Evanston, IL 60201. 
